March 2024 – Genprex

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

March 22, 2024Kalyn Dabbs Press Releases

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

March 19, 2024Kalyn Dabbs Press Releases

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

March 12, 2024Kalyn Dabbs Acclaim 1 Press Releases

Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors applicable to Genprex’s Acclaim-2 and Acclaim-3 clinical trials

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

March 6, 2024Kalyn Dabbs Acclaim 2 Press Releases

Reqorsa® Immunogene Therapy May be a Potential Therapy for ALK-Positive Lung Cancer